Posts

Posted on

Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, is pleased to announce that its Board of Directors has authorized management to explore taking its subsidiary, Pearsanta, Inc. (“Pearsanta”), public via a proposed initial public offering (“IPO”) in 2025. This decision aligns with Aditxt’s mission to secure and develop transformative health innovations, positioning them for accelerated growth and broader market impact.

Pearsanta, a precision diagnostic company, has advanced its development and operational capabilities, particularly in early cancer detection, by leveraging its proprietary Mitomic® Technology platform. The proposed Pearsanta IPO is intended to provide critical resources to accelerate Pearsanta’s growth and expand its market presence.

“Cancer remains to be one of humanities biggest health challenges. Pearsanta’s launch of its Mitomic® Technology platform for the early detection of cancer, reflects our commitment to identifying, developing and accelerating some of the most promising health innovations,” said Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt. “The Board’s authorization to explore this path is a key first step in positioning Pearsanta for a successful global launch.”

“The proposed IPO marks a transformative moment for Pearsanta as we seek to bring our groundbreaking Mitomic® Technology platform to the global stage. We believe this milestone will enable us to accelerate the commercialization of our early cancer detection solutions, empowering clinicians with tools for earlier and more accurate diagnoses,” said Chris Mitton, President of Pearsanta. “Our focus remains on addressing critical unmet needs in healthcare, and this step is intended to position us to make a meaningful impact in the fight against cancer worldwide.”

About Aditxt

Aditxt, Inc.® is a social innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress.

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Appili and $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem’s senior secured noteholder; should Aditxt fail to secure these funds, Evofem’s senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. On December 23, 2024, Evofem announced the cancellation of its special stockholders meeting and the withdrawal of the merger proposal with Aditxt from consideration by the stockholders. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

For more information, www.aditxt.com.

About Pearsanta

Pearsanta is at the forefront of precision health, focusing on early cancer detection through advanced diagnostic technologies. Its proprietary Mitomic Technology Platform leverages the unique properties of mitochondrial DNA to detect cancer and other diseases with high accuracy via non-invasive, blood-based liquid biopsy tests. Pearsanta’s asset portfolio also includes a range of other innovative diagnostic technologies, all aimed at transforming early disease detection and monitoring, enabling more informed treatment decisions, and ultimately improving patient outcomes.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; expected usage of the Company’s ELOC and ATM facilities; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Aditxt, Inc.

Corporate Communications

Jeff Ramson, PCG Advisory, Inc.

T: 646-863-6893

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Health Technology Oncology

MEDIA:

Posted on

BIOA CLASS ACTION NEWS: BioAge Labs, Inc. Investors are Notified of Upcoming March 10 Court Deadline – Contact BFA Law if You Suffered Losses (NASDAQ:BIOA)

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws.

If you invested in BioAge, you are encouraged to obtain additional information by visitinghttps://www.bfalaw.com/cases-investigations/bioage-labs-inc.

Investors have until March 10, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased stock pursuant and/or traceable to BioAge’s registration statement for its initial public offering held on or about September 26, 2024.   The case is pending in the U.S. District Court for the Northern District of California and is captioned Soto v. BioAge Labs, Inc., et al., No. 25-cv-196.

Why was BioAge Sued
under the Federal Securities Laws?

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The Company’s lead product candidate, azelaprag, is an orally available small-molecule agonist of the apelin receptor (APJ), designed to enhance weight loss.

As alleged, BioAge’s IPO documents discussed its ongoing STRIDES Phase 2 trial of azelaprag in combination with GLP-1R agonists for enhanced weight loss. BioAge stated that it was collaborating with Eli Lilly and Company (“Lilly”) in connection with STRIDES, and that Lilly would be advising and assisting on all aspects of the trial’s design and execution. BioAge also stated that it anticipated topline results in Q3 2025 and discussed the potential for a second Phase 2 clinical trial. As alleged, BioAge’s statements conveyed to investors that there were no safety concerns and that it expected top line results to meet its primary endpoint goals.

In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company terminated the trial and ceased further enrollment.

The Stock Declines as the Truth is Revealed

On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. The Company stated that the decision to discontinue the STRIDES trial of azelaprag “became clear” due to “the emerging safety profile of the current doses tested[.]” This news caused the price of BioAge stock to decline over 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.

Click here for more information:

https://www.bfalaw.com/cases-investigations/bioage-labs-inc

.

What Can You Do?

If you invested in BioAge you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/bioage-labs-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/bioage-labs-inc

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

NXT CLASS ACTION NEWS: Nextracker Inc. Investors are Notified of Upcoming February 25 Court Deadline – Contact BFA Law if You Suffered Losses (NASDAQ:NXT)

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Nextracker Inc. (NASDAQ: NXT) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Nextracker, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/nextracker-inc.

Investors have until February 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Nextracker stock.   The case is pending in the U.S. District Court for the Northern District of California and is captioned Weber v. Nextracker Inc., et al., No. 24-cv-9467.

Why was Nextracker Sued for Securities Fraud?

Nextracker provides software that enables solar panels to follow the sun’s movement across the sky and related products and services. Nextracker’s customers include solar project developers and owners.

During the relevant period, Nextracker minimized the impact of project delays on its business, claiming that the delays were isolated to individual projects, that the Company was better at managing project timelines than its competitors, and that favorable demand trends more than offset any adverse effects stemming from project delays.

In truth, Nextracker’s ability to convert its backlog to revenue was hampered by permitting delays as well as panel availability and interconnection to a far greater extent than previously disclosed. In addition, the purported favorable demand trends and Nextracker’s management of project timeliness had not effectively offset the negative impact of these project delays.

The Stock Declines as the Truth is Revealed

On August 1, 2024, Nextracker announced its financial results for its fiscal Q1 2025, revealing that revenue declined to $720 million, from $737 million in the prior quarter, and failed to raise guidance for the first time since it became a public company. On the same-day earnings call, Nextracker admitted that “it is taking longer for projects to be fulfilled in real life due to” “construction permits or interconnection delays.” The Company also stated that only “80% of that backlog is expected to be realized over the next eight quarters,” which it acknowledged was “a bit of a shift” from its prior commentary on its backlog conversion rate.

On this news, the price of Nextracker stock fell 15% over the course of two trading days, from a closing price of $46.83 per share on August 1, 2024 to $39.81 per share on August 5, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/nextracker-inc

.

What Can You Do?

If you invested in Nextracker you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/nextracker-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/nextracker-inc

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

ASML DEADLINE TODAY: ASML Holding N.V. Investors are Notified that Today is the Final Deadline in Class Action – Contact BFA Law (NASDAQ:ASML)

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit for violations of the federal securities laws against ASML Holding N.V. (NASDAQ: ASML) and certain of the Company’s senior executives.

If you invested in ASML, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/asml-holding-nv.

Investors have until January 13, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in ASML ordinary shares, call options, and/or put options.   The case is pending in the U.S. District Court for the Southern District of New York and is captioned Matar v. ASML Holding N.V., et al., No. 24-cv-9908.

What is the Lawsuit About?

ASML is a leading supplier to the semiconductor industry, providing photolithography machines to chipmakers that are used in the semiconductor fabrication process.

The complaint alleges that ASML repeatedly represented to shareholders that new export controls on semiconductor technology announced by the Dutch government would not have a material effect on ASML’s financial outlook, and that ASML was on a path to recovery in its sales.

On October 15, 2024, ASML announced earnings significantly lower than expectations. The Company attributed this to a market that was “taking longer to recover” and admitted that “[i]t now appears the recovery is more gradual than previously expected.” On this news, the price of the Company’s stock fell 16%, from a closing price of $872.27 per share on October 14, 2024, to $730.43 per share on October 15, 2024.

Then, during the accompanying earnings call with investors on October 16, 2024, the Company attributed the poor earnings results to “a reflection of the slow recovery in the traditional [semiconductor] end markets as customers remain cautious in the current environment.” The Company also disclosed that the decline in ASML’s sales to China would also negatively impact the Company’s gross margins. On this news, the price of the Company’s stock fell 6.4%, from a closing price of $730.43 per share on October 15, 2024, to $683.52 per share on October 16, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/asml-holding-nv

.

What Can You Do?

If you invested in ASML you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/asml-holding-nv

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/asml-holding-nv

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

MQ CLASS ACTION NEWS: Marqeta, Inc. Investors are Notified of Upcoming February 7 Court Deadline – Contact BFA Law if You Suffered Losses (NASDAQ:MQ)

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Marqeta, Inc. (NASDAQ: MQ) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Marqeta, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/marqeta-inc.

Investors have until February 7, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Marqeta securities.   The first-filed case is pending in the U.S. District Court for the Northern District of California and is captioned Wai v. Marqeta, Inc., et al., No. 24-cv-8874.

Why was Marqeta Sued for Securities Fraud?

Marqeta is a financial technology company that provides a card issuing platform, enabling businesses to create and manage customized payment cards. During the relevant period, Marqeta discussed its ability to attract and retain customers while continuing to achieve operational efficiencies given the purported investments it already made into its compliance infrastructure.

In truth, it is alleged that at the time the statements were made, Marqeta experienced longer customer onboarding timelines caused by heightened regulatory scrutiny and insufficient investments into the Company’s compliance apparatus.

The Stock Declines as the Truth is Revealed

On November 4, 2024, the Company reported its third quarter 2024 financial results and cut its full year 2025 growth outlook, due to “heightened scrutiny of the banking environment and specific customer program changes.” On the earnings call the same day, the Company revealed that “the regulatory scrutiny” had “clearly ratcheted up” in the “first few months of 2024.” Marqeta also admitted that the impact the increased scrutiny had on the Company’s business “became apparent over the last few months.”

This news caused the price of the Company’s stock to fall over 42%, from a closing price of $5.95 per share on November 4, 2024, to $3.42 per share on November 5, 2024.

Click here if you suffered losses:

https://www.bfalaw.com/cases-investigations/marqeta-inc

.

What Can You Do?

If you invested in Marqeta you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases-investigations/marqeta-inc

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases-investigations/marqeta-inc

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

High Roller Technologies Provides Business Update with Key Milestones

– Strategic expansion efforts to increase total addressable market 

– 54% increase in QoQ first time depositors and 37% QoQ increase in active players

– Continue to show solid growth metrics; last reported 30% QoQ revenue growth

Las Vegas, Nevada, Jan. 13, 2025 (GLOBE NEWSWIRE) — High Roller Technologies, Inc. (“High Roller” and the “Company”) (NYSE American: ROLR), operator of www.HighRoller.com and www.Fruta.com, each a premium brand in online gaming and a destination for high rollers, today provided a corporate update with recent milestones the Company has reached during a transformative year from a private to a publicly traded company on the NYSE American. Since the IPO, and listing on a senior exchange, High Roller and its brands have seen better exposure and visibility to the overall market, both with new and existing shareholders.

Financial and Operational Achievements

  • Company reported a significant 30% quarter-over-quarter revenue growth for the three months ended September 30, 2024: bringing total revenue to $7.5 million through cost optimization and strong marketing performance
  • Company successfully completed IPO on the NYSE American in October 2024 and raised gross proceeds of $10 million; net proceeds used for expansion, new user acquisition, launching new brands/verticals, and working capital
  • Had a 54% quarter-over-quarter increase in first time depositors from 13,422 in Q3 2024 to 20,669 in Q4 2024, and a 37% increase in active players from 25,273 in Q3 2024 to 34,653 in Q4 2024

Strategic Planning and Industry Recognition Updates

  • In January 2025, appointed industry veteran Kristofer Muscat as its new Chief Operating Officer where he will oversee operational strategy, drive growth initiatives, and enhance High Roller’s commitment to delivering premium experiences in the online gambling and iCasino gaming industry
  • Won multiple prestigious gaming awards at the 2024 WN iGaming Summit, including Casino Operator of the Year, and High Roller CMO receiving iGaming Leader of the Year; High Roller was also awarded Best Player Retention 2024 at the SiGMA Europe B2C Awards           
  • Continued to build on the Company’s vision of providing one of the most immersive and engaging online casino gaming in the industry
  • Looking at expanding product offerings to over 4,000+ games, including deeper market penetration and expanding the addressable market in Ontario, Canada

Ben Clemes, Chief Executive Officer at High Roller Technologies, commented, “We saw solid revenue growth of 60% from 2022 to 2023, and as of our last published Q3 results, we had a 30% QoQ increase in revenue which we were tremendously proud of. Post-IPO, progress of our business has been excellent, as we’ve seen increases in first time depositors and active users QoQ across our brands. This growth in new users and deposits speak volumes to our ability to execute on our strategic growth.”

He continued, “The IPO provided us the capital we have needed to deploy our marketing efforts, and we have already seen better than expected returns on the marketing spend, which we will continue to optimize in the coming months. In addition, we have allocated capital to start the license process in Ontario which will increase our total addressable market substantially and is a natural expansion to our existing Canadian business.”

About High Roller Technologies, Inc.

High Roller Technologies, Inc. is a leading global online gaming operator, known for its innovative casino brands, High Roller and Fruta, listed under the ticker ROLR on the NYSE American. The Company delivers a cutting-edge real-money online casino platform that is intuitive and user-friendly. With a diverse portfolio of over 4,000 premium games from more than 50 leading game providers, High Roller Technologies serves a global customer base, offering an immersive and engaging gaming experience in the rapidly expanding multi-billion iGaming industry. The online casino features enhanced search engine optimization, machine learning, seamless direct API integrations, faster load times, and superior scalability.

As an award-winning operator, High Roller Technologies continues to redefine the future of online gaming through innovation, performance, and a commitment to excellence. For more information, please visit the High Roller Technologies, Inc. investor relations website, X, Facebook, and LinkedIn pages.

Forward Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact


[email protected]

800-460-1039



Posted on

LifeVantage Launches 2025 Vision with “Drive ERA” Theme and International Expansion Plans for Evolve Compensation Plan and the MindBody GLP-1 System™

New Innovations and Incentives Empower Consultants to Accelerate Business Growth in 2025

SALT LAKE CITY, Jan. 13, 2025 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, hosted its annual Global Kickoff on Saturday, January 11, 2025. Thousands of the company’s independent Consultants around the world joined the live broadcast to celebrate the company’s bold vision for 2025, which emphasized momentum, continued innovation, and international expansion of the MindBody GLP-1 System™. The company also announced that the Philippines, Taiwan, Hong Kong, and Singapore markets will transition to the Evolve Compensation Plan on March 1, with Thailand, the final market to move to Evolve, planned for transition by the end of the fiscal year.

An energetic tone was set early in the broadcast by President and CEO Steve Fife, who introduced the 2025 theme: “Drive ERA.” The theme’s core message encourages Consultants to build on the momentum of the previous year, find their internal motivations, and take proactive control of their success.

“Over the last several years and during the course of our LV360 transformation we’ve laid the foundation for growth by equipping our Consultants with tools to thrive,” said Fife. “Now, in 2025, we’re challenging the field to leverage that momentum, lean into the possibilities ahead, set ambitious goals, and drive their businesses to new heights.”

Highlights from the Global Kickoff Event

MindBody System™ International Rollout

LifeVantage announced the global launch schedule for its newest product innovation, the MindBody GLP-1 System™, starting in Japan on March 15, 2025. Consultants in Australia, New Zealand, Mexico, Europe, and Thailand will also have access to the product that same day, with the full launch and availability for customers coming April 24, 2025, coinciding with the company’s Global Convention.

Healthy Weight Stack Study Results

A major announcement at the event was the release of new findings from a third-party cell study on the synergy between the patent-pending MindBody GLP-1 System™ and the proprietary Protandim® Nrf2 Synergizer® which together comprise the Healthy Weight Stack. Results showed that the combination of the products not only amplified key benefits of each individual product, but also led to unexpected additional benefits through the activation of 22 new genes.*||

Key findings include:

  • Synergistic Organ Health Activation: 22 new genes were activated to help cells restore, rebuild, and renew optimal organ strength, structure, and communication to help the body think faster, feel stronger and age smarter.*||
  • Enhanced Antioxidant Defense: Four additional antioxidant pathways were activated, supporting Protandim Nrf2 Synergizer’s ability to help cells make antioxidants they need to combat oxidative stress and promote cellular resilience.*||
  • Amplified Fat Metabolism: Nine additional fat and fatty acid metabolism pathways were activated, improving MindBody GLP-1 System’s efficacy by optimizing the body’s ability to use and distribute fat effectively and enhancing the breakdown of unhealthy visceral fat in the midsection.*||‡

More details on the Healthy Weight Stack study were included in a press release that hit wires earlier today.

New and Updated Incentive Programs

LifeVantage introduced the Drive ERA Incentive, which runs from January to March 2025. The program rewards Consultants for achievements in enrolling, retaining, and advancing, building on the success of similar incentives that ran in calendar 2024.

Evolve Perks, the Consultant recognition program, was updated for 2025 with new rank maintenance gifts and Growth Summit qualification dates. Consultants in Australia, New Zealand, Taiwan, Hong Kong, Singapore, Thailand, and the Philippines, can also work to qualify for an exclusive getaway to Vietnam.

“In 2025, our focus is on empowering Consultants to seize new opportunities, achieve ambitious goals, and create lasting impact,” said Fife. “This is the year all LifeVantage markets will be on our industry-leading Evolve Compensation Plan as well as have access to the revolutionary MindBody GLP-1 System. It’s a pivotal moment for the entire LifeVantage community to turn vision into reality and elevate success.”

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System™, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs.* Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

Public Relations Contact:

Madeline Gossett, CerconeBrownCompany
(704) 620-7673
[email protected]

Investor Relations Contact:

Reed Anderson, ICR
(646) 277-1260
[email protected]

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

*||
Results based on a cell culture study on active ingredient blends in the MindBody GLP-1 System and Protandim Nrf2 Synergizer.

‡Results may vary. Typical weight loss using this product in a 12-week weight management program is 1–2 pounds per week. This product should be used in conjunction with a healthy diet and regular exercise. Consult with a healthcare provider before starting any weight loss program.



Posted on

StepStone Group Closes Inaugural Infrastructure Co-investment Fund, Surpassing $1 billion

Expands infrastructure investment solutions beyond separate accounts, broadening access for investors

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP), a global private markets investment firm, today announced the final close of StepStone Infrastructure Co-Investment Partners 2022 (“SICP” or the “Fund”) and related separate accounts with over $1.4 billion of capital commitments.

SICP closed with approximately $1.2 billion of capital commitments, significantly surpassing its target, thanks to strong support from a diverse group of limited partners from around the world.

Through SICP, StepStone invests alongside leading global infrastructure sponsors in select transactions according to their expertise. The Fund pursues a mix of core-plus and value-add opportunities and seeks to capitalize on major secular trends such as the energy transition, the growth of digital connectivity and AI.

StepStone is among the most active infrastructure investors in the world, deploying an average of $13 billion each year over the past three years. This scale, coupled with a team of more than 80 infrastructure professionals and specialists, allows StepStone to support its clients, leveraging its deep GP relationships and access to a large pool of opportunities across primary fund investments, secondaries and co-investments.

“The close of SICP marks a significant milestone as we expand the solutions we offer our clients,” said James O’Leary, Partner and Head of StepStone Infrastructure & Real Assets. “We would like to thank our investors for their trust and support. There continues to be attractive investment opportunities in infrastructure, and we look forward to working closely with investors to find the optimal way for them to include this compelling asset class in their portfolios.”

Latham & Watkins LLP advised on the formation of the Fund.

About StepStone

StepStone Group Inc. (Nasdaq: STEP) is a global private markets investment firm focused on providing customized investment solutions and advisory and data services to its clients. As of September 30, 2024, StepStone was responsible for approximately $682 billion of total capital, including $176 billion of assets under management. StepStone’s clients include some of the world’s largest public and private defined benefit and defined contribution pension funds, sovereign wealth funds and insurance companies, as well as prominent endowments, foundations, family offices and private wealth clients, which include high-net-worth and mass affluent individuals. StepStone partners with its clients to develop and build private markets portfolios designed to meet their specific objectives across the private equity, infrastructure, private debt and real estate asset classes.

Contacts

Shareholder Relations:

Seth Weiss
[email protected]
+1 (212) 351-6106

Media:

Brian Ruby / Chris Gillick / Matt Lettiero, ICR
[email protected]
+1 (203) 682-8268



Posted on

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC

Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations

Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026

Cash and investments expected to fund operating plan into late 2026

SOUTH SAN FRANCISCO and SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today provided early Phase 1b combination data for ORIC-944, operational highlights for 2024, and anticipated upcoming milestones.

“We made strong progress on multiple fronts in 2024, most notably with the initiation of multiple cohorts for ORIC-114 in NSCLC and ORIC-944 in mCRPC. We also forged three strategic collaborations with leading pharma partners, strengthened our leadership team to expand functional capabilities, and completed a $125 million PIPE financing, extending our cash runway into late 2026,” said Jacob M. Chacko, M.D., president and chief executive officer. “These accomplishments position us well for 2025 and beyond, with seven anticipated data readouts over the next 18 months as we advance toward potentially initiating registrational studies for ORIC-114 in the second half of 2025 and for ORIC-944 in early 2026.”

Updated Phase 1b Combination Data for ORIC-944

ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via allosteric targeting of the embryonic ectoderm development (EED) subunit. ORIC-944 was initially evaluated as a single agent in a Phase 1b trial in patients with advanced prostate cancer and demonstrated potential best-in-class drug properties, including a clinical half-life of approximately 20 hours, robust target engagement, and a favorable safety profile.

In mid-2024, the Company initiated once daily dosing of ORIC-944 in combination with 240 mg QD apalutamide or with 600 mg BID darolutamide, as part of the ongoing Phase 1b trial in patients with metastatic castration resistant prostate cancer (mCRPC). As of the December 10, 2024 data cut-off, the Company completed the first two ORIC-944 dose escalation cohorts (n=6 patients) for the apalutamide combination. This initial experience demonstrated:

  • Deep prostate-specific antigen (PSA) decreases across both the 600 mg and 800 mg dose cohorts; 3 of 6 patients achieved confirmed PSA50 responses, of which 2 achieved confirmed PSA90 responses. All the PSA responses were maintained at ≥12 weeks, including a durable confirmed PSA90 response ongoing at 38 weeks.
  • Well-tolerated safety, with primarily Grade 1 and Grade 2 treatment related adverse events (TRAE), consistent with PRC2 and androgen receptor (AR) inhibition, and one Grade 3 TRAE of fatigue (patient remains on treatment without dose modification). The first two dose levels cleared without dose limiting toxicities or treatment discontinuations related to safety. Dose escalation is ongoing.

Dose escalation for the combination of ORIC-944 with darolutamide is also ongoing with the first dose cohort completed and the second enrolling. Preliminary clinical activity seen to date is consistent with the apalutamide combination cohort.

2024 Key Accomplishments


ORIC-114

: a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor

  • Entered into a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous (SC) amivantamab for the 1L treatment of NSCLC patients with EGFR exon 20 insertion mutations.
  • Initiated a cohort to evaluate ORIC-114 monotherapy for the treatment of patients with 1L treatment-naïve EGFR exon 20 insertion NSCLC.
  • Announced the completion of the dose escalation portion of the Phase 1b trial of ORIC-114 and the selection of two provisional recommended phase 2 doses; after which, first patients were dosed across three expansion cohorts in the Phase 1b trial of ORIC-114 in patients with mutated non-small cell lung cancer (NSCLC), including 2L EGFR exon 20 insertion (EGFR exon 20 inhibitor naïve), 2L+ HER2 exon 20 insertion, and 2L+ EGFR atypical mutations.
  • Presented preclinical data demonstrating potential best-in-class properties, including potency and selectivity, of ORIC-114 to treat NSCLC harboring EGFR exon 20 insertions and other atypical EGFR mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.


ORIC-944

: a potent and selective allosteric inhibitor of PRC2

  • Initiated dosing of ORIC-944 in combination with ERLEADA® (apalutamide) and in combination with NUBEQA® (darolutamide) in mid-2024 in the ongoing Phase 1b trial for prostate cancer.
  • Entered into clinical trial collaboration and supply agreements with Johnson & Johnson and Bayer to support the ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of prostate cancer.
  • Reported initial Phase 1b single agent data for ORIC-944 in metastatic prostate cancer supporting advancement into combination development and demonstrating the potential as a best-in-class PRC2 inhibitor, including a clinical half-life of ~20 hours, robust target engagement, no signs of CYP autoinduction that was observed with first-generation PRC2 inhibitors, and a generally well-tolerated safety profile.
  • Presented preclinical data at the 2024 AACR Annual Meeting demonstrating superior drug properties and synergy data in prostate cancer models, reinforcing the promise of ORIC-944 as a potential best-in-class treatment for combination with AR inhibitors.


Corporate Highlights:

  • Strengthened cash position and runway with a $125 million private placement financing from new and existing healthcare specialist funds.
  • Expanded the leadership team with the appointment of industry veteran Keith Lui as Senior Vice President of Commercial and Medical Affairs.

Anticipated Program Milestones

ORIC anticipates the following upcoming data milestones:

  • ORIC-114 (NSCLC):
    • 1H 2025: 2L EGFR exon 20 and 2L+ HER2 exon 20
    • 2H 2025: 2L+ EGFR atypical
    • 1H 2026: 1L EGFR exon 20
    • Mid-2026: 1L EGFR exon 20 combination with SC amivantamab and 1L EGFR atypical
  • ORIC-944 (mCRPC):
    • 4Q 2025 / 1H 2026: Combination with AR inhibitors

Financial Guidance

As of September 30, 2024, cash, cash equivalents and investments totaled $282.4 million, which the company expects will be sufficient to fund its operating plan into late 2026.

Presentation and Webcast

Jacob M. Chacko, M.D., president and chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. PT. A live webcast will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers, and (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the continued clinical development of ORIC-114 and ORIC-944; statements regarding the potential best-in-class properties of ORIC-114 and ORIC-944; clinical outcomes from combination studies with ORIC-944, which may materially change as patient enrollment continues or more patient data become available; the development plans and timelines for ORIC-114, ORIC-944 and ORIC’s other product candidates; the potential advantages of ORIC-114, ORIC-944 and ORIC’s other product candidates and programs; plans underlying ORIC’s clinical trials and development; anticipated program milestones, including timing of program and data updates and the initiation of registrational studies; the period over which ORIC estimates its existing cash, cash equivalents and investments will be sufficient to fund its current operating plan; and statements by the company’s chief executive officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC’s product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section titled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:

Dominic Piscitelli, Chief Financial Officer
[email protected]
[email protected]



Posted on

IonQ Announces New $21.1 Million Project with United States Air Force Research Lab (AFRL) to Push Boundaries on Secure Quantum Networking

IonQ Announces New $21.1 Million Project with United States Air Force Research Lab (AFRL) to Push Boundaries on Secure Quantum Networking

Together, IonQ and AFRL expect to create groundbreaking capabilities to establish free-space optical links from ground stations to drones

This project highlights the strong market demand for IonQ’s innovative quantum computing and networking products

IonQ’s recent acquisition of Qubitekk extends networking expertise and opens new avenues for innovation with project partners

COLLEGE PARK, Md.–(BUSINESS WIRE)–
IonQ (NYSE: IONQ), a leader in the quantum computing and networking industries, today announced a new $21.1 million project via Qubitekk, Inc. to work with the United States Air Force Research Lab (AFRL).

This new effort represents another significant milestone for IonQ as it collaborates with AFRL to install quantum network infrastructure at the Innovare Advancement Center in Rome, New York. Quantum networks are poised to become important for secure infrastructure, as the technology enables multiple nodes to communicate via entangled qubits, offering secure communications, precise timing synchronization, and a foundation for distributed quantum computing.

The new quantum project will support AFRL’s Quantum Information Science & Technology Branch at the Information Directorate and its quantum networking and computing research. Under this effort, IonQ will:

  • Develop a network with high-performing access points to drive the interoperability of quantum computers and networked devices

  • Deliver networking hardware to expand compatibility with existing telecommunication infrastructure

  • Collaborate with AFRL to create ground-breaking capabilities in establishing free-space optical links from ground stations to uncrewed aerial systems (UASs)

“We are thrilled to deepen our collaboration with AFRL to provide advanced quantum network technologies for the U.S. Air Force, leveraging the team and technology of our recent Qubitekk asset acquisition” said Peter Chapman, President and CEO of IonQ. “This is an exciting year for IonQ and the quantum industry at large, as we continue to see significant revenue growth for our networking technologies and strong demand for our IonQ Forte Enterprise and Tempo quantum computing systems.”

“Advancing quantum technology is crucial for maintaining our nation’s technological leadership. Our partnership with the industry signifies a substantial commitment to nurturing this vital competitive edge,” remarked Michael Hayduk, Deputy Director of the Air Force Research Laboratory, Information Directorate. “We are devoted to exploring innovative advancements in quantum computing and networking that will enhance our national security capabilities.

The new 2024 Q4 project with AFRL builds on recent contracts such as the $54.5 million agreement signed in September 2024 with AFRL and the contract with the Applied Research Laboratory for Intelligence and Security (ARLIS) to design a first-of-its-kind, networked system for blind quantum computing, and other significant contracts. This momentum is reinforced by IonQ’s Q3 2024 financial results, with the company doubling its year-over-year revenue for the quarter.

To learn more about IonQ and its latest system news and business developments, visit https://ionq.com.

About IonQ

IonQ, Inc. is a leader in the quantum computing and networking industry, delivering high-performance systems aimed at solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Newsweek’s 2025 Excellence Index 1000, Forbes’ 2025 Most Successful Mid-Cap Companies list, Built In’s 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the terms “will,” “expect,” “exceeding,” “expectations,” “potential,” “progressing,” “trajectory,” “poised,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the expected creation of certain technologies, deliverables and capabilities; the expected future significance, capabilities and security of quantum networks; IonQ’s reliance on Qubitekk, Inc. and the former Qubitekk team for project and contract delivery; the potential benefits of IonQ’s work with project partners; and the problems that can be solved by IonQ’s quantum computers and networks. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: any disruptions and other problems with our operations including research and development, hardware, systems, components or facilities; IonQ’s ability to attract and retain its key employees and other personnel with specialized knowledge; any changes or inadequacies in IonQ’s quantum computing and networking capabilities and plans; IonQ’s relatively limited history in development quantum networking technologies; the capability of our quantum systems and quantum networks to provide certain capabilities and advantages; changes in laws and regulations affecting IonQ, its assets or the quantum sector generally; and IonQ’s ability to implement its business plans, technical roadmap, and projects. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.

IonQ Media:

Jane Mazur

[email protected]

IonQ Investor:

[email protected]

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Technology Contracts Semiconductor Security Software Networks Government Technology Hardware Defense Artificial Intelligence

MEDIA:

Logo
Logo